Inclusion Criteria:

- Pts have confirmed diagnosis of recurrent primary WHO grade IV malignant glioma (MG).
Pts w recurrent disease whose diagnostic pathology confirmed GBM will not need
re-biopsy. Pts w prior low-gr glioma / anaplastic glioma are eligible if histologic
assessment demonstrates transformation to GBM

- Age >18 yrs

- Interval of >2 wk between prior surgical resection

- Interval of >12 wks between prior external-beam radiation therapy (XRT) unless there
is either: histopathologic confirmation of recurrent tumor; new enhancement on MRI
outside of XRT treatment field; / progressive radiographic changes after XRT/temo as
well as after adjuvant, post-XRT temo

- Interval of >4 wks between chemo & enrollment on protocol unless: unequivocal
evidence of tumor progression; & pt has recovered fully from all toxicity associated
w prior surgery, XRT/chemo. Pts treated w chemo agents such as VP-16 who would
normally be retreated after shorter intervals may be treated at usual starting time
even if <4 wks from last prior dose chemo

- Karnofsky performance score >= 70 percent

- Hematocrit >29 percent, absolute neutrophil count (ANC) >1,500 cells/microliter,
platelets >100,000 cells/microliter

- Serum creatinine <1.5 mg/dl, serum glutamic oxaloacetic transaminase (SGOT) &
bilirubin <1.5 x upper limit of normal (ULN); fasting plasma triglyceride &
cholesterol < gr1

- For pts on corticosteroids, dose should not be increasing for >7 days prior to
baseline Gd-MRI of brain if medically appropriate

- Pts in enzyme inducing antiepileptic drug cohort must be on stable dose of
p450-inducing EIAED for >2 wks. Pts in non-EIAED cohort must not receive any
p450-EIAED for >2 wks prior to & during participation in trial

- Signed informed consent approved by Institutional Review Board (IRB) prior to pt
entry

- If sexually active, pts will take contraceptive measures for duration of treatments &
for 3 months following discontinuation of Erlotinib

- Pts who have had prior bevacizumab are eligible however interval of >6 weeks must
have elapsed since their last dose

Exclusion Criteria:

- Prior mammalian target of rapamycin (mTOR) directed therapy

- Prior epidermal growth factor receptor (EGFR)-directed therapy

- Female pts are pregnant/breast feeding, or adults of reproductive potential not
employing effective method of birth control. Women of childbearing potential must
have negative serum pregnancy test <72 hours prior to administration of Erlotinib

- Co-medication that may interfere w study results

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection requiring IV antibiotics, symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, hyperlipidemia not controlled w medication,
psychiatric illness/social situations that would limit compliance w study
requirements,/disorders associated w significant immunocompromise

- Acute/chronic liver disease

- Impairment of GI function/GI disease that may significantly alter absorption of
Erlotinib

- Pts who have received investigational drugs <4 wks prior to entry on study or who
have not recovered from toxic effects of such therapy

- Pts who have received biologic, immunotherapeutic/cytostatic agents <1 wk prior to
entry on study/have not recovered from toxic effects of such therapy

- Pt is <5 yrs free of another primary malignancy except: if other primary malignancy
is not currently clinically significant/requiring active intervention,/if other
primary malignancy is basal cell skin cancer/cervical carcinoma in situ. Existence of
any other malignant disease is not allowed

- Pts have had any surgery other than resection of brain tumor <2 wks prior to entry on
study/have not recovered from side effects of such therapy

- Pts unwilling to/unable to comply w protocol

- Pts w acute/chronic renal insufficiency/those w acute renal insufficiency of any
severity due to hepato-renal syndrome/in peri-operative liver transplantation period